Background: The assortment of patients based on the underlying pathophysiology is central to preventing recurrent stroke after a transient ischemic attack and minor stroke (TIA-MS). The causative classification of stroke (CCS) and the A-S-C-O (A for atherosclerosis, S for small vessel disease, C for Cardiac source, O for other cause) classification schemes have recently been developed. These systems have not been specifically applied to the TIA-MS population. We hypothesized that both CCS and A-S-C-O would increase the proportion of patients with a definitive etiologic mechanism for TIA-MS as compared with TOAST. Methods: Patients were analyzed from the CATCH study. A single-stroke physician assigned all patients to an etiologic subtype using published algorithms for TOAST, CCS and ASCO. We compared the proportions in the various categories for each classification scheme and then the association with stroke progression or recurrence was assessed. Results: TOAST, CCS and A-S-C-O classification schemes were applied in 469 TIA-MS patients. When compared to TOAST both CCS (58.0 vs. 65.3%; p < 0.0001) and ASCO grade 1 or 2 (37.5 vs. 65.3%; p < 0.0001) assigned fewer patients as cause undetermined. CCS had increased assignment of cardioembolism (+3.8%, p = 0.0001) as compared with TOAST. ASCO grade 1 or 2 had increased assignment of cardioembolism (+8.5%, p < 0.0001), large artery atherosclerosis (+14.9%, p < 0.0001) and small artery occlusion (+4.3%, p < 0.0001) as compared with TOAST. Compared with CCS, using ASCO resulted in a 20.5% absolute reduction in patients assigned to the ‘cause undetermined' category (p < 0.0001). Patients who had multiple high-risk etiologies either by CCS or ASCO classification or an ASCO undetermined classification had a higher chance of having a recurrent event. Conclusion: Both CCS and ASCO schemes reduce the proportion of TIA and minor stroke patients classified as ‘cause undetermined.' ASCO resulted in the fewest patients classified as cause undetermined. Stroke recurrence after TIA-MS is highest in patients with multiple high-risk etiologies or cryptogenic stroke classified by ASCO.

Keywords:
TOAST, ASCO, Causative classification system, Transient ischemic attack, Minor stroke, Etiologies
1.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
2.
Matarin M, Brown WM, Hardy JA, Rich SS, Singleton AB, Brown RD Jr, et al: Association of integrin alpha2 gene variants with ischemic stroke. J Cereb Blood Flow Metab 2008;28:81-89.
3.
Lee LJ, Kidwell CS, Alger J, Starkman S, Saver JL: Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. Stroke 2000;31:1081-1089.
4.
Ay H, Benner T, Arsava EM, Furie KL, Singhal AB, Jensen MB, et al: A computerized algorithm for etiologic classification of ischemic stroke: the causative classification of stroke system. Stroke 2007;38:2979-2984.
5.
Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG: New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 2009;27:502-508.
6.
Marnane M, Duggan CA, Sheehan OC, Merwick A, Hannon N, Curtin D, et al: Stroke subtype classification to mechanism-specific and undetermined categories by TOAST, A-S-C-O, and causative classification system: direct comparison in the north Dublin population stroke study. Stroke 2010;41:1579-1586.
7.
Wolf ME, Sauer T, Alonso A, Hennerici MG: Comparison of the new ASCO classification with the TOAST classification in a population with acute ischemic stroke. J Neurol 2012;259:1284-1289.
8.
Bal S, Patel SK, Almekhlafi M, Modi J, Demchuk AM, Coutts SB: High rate of magnetic resonance imaging stroke recurrence in cryptogenic transient ischemic attack and minor stroke patients. Stroke 2012;43:3387-3388.
9.
Ferrari J, Knoflach M, Kiechl S, Willeit J, Schnabl S, Seyfang L, et al: Early clinical worsening in patients with TIA or minor stroke: the Austrian stroke unit registry. Neurology 2010;74:136-141.
10.
Coutts SB, Modi J, Patel SK, Demchuk AM, Goyal M, Hill MD, et al: CT/CT angiography and MRI findings predict recurrent stroke after transient ischemic attack and minor stroke: results of the prospective CATCH study. Stroke 2012;43:1013-1017.
11.
Dennis MS, Bamford JM, Sandercock PA, Warlow CP: Incidence of transient ischemic attacks in Oxfordshire, England. Stroke 1989;20:333-339.
12.
Amort M, Fluri F, Weisskopf F, Gensicke H, Bonati LH, Lyrer PA, et al: Etiological classifications of transient ischemic attacks: subtype classification by TOAST, CCS and ASCO - a pilot study. Cerebrovasc Dis 2012;33:508-516.
13.
Cotter PE, Belham M, Martin PJ: Towards understanding the cause of stroke in young adults utilising a new stroke classification system (A-S-C-O). Cerebrovasc Dis 2012;33:123-127.
14.
Arsava EM, Ballabio E, Benner T, Cole JW, Delgado-Martinez MP, Dichgans M, et al: The causative classification of stroke system: an international reliability and optimization study. Neurology 2010;75:1277-1284.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.